BPMC
Blueprint Medicines Corp
Halal Rating :
Last Price
$110.07
Last updated:
Market Cap
-
7D Change
6.49%
1 Year Change
32.58%
Company Overview
Industries
Exchange
Next Earnings Date
Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers, rare diseases, and cancer immunotherapy. The company develops and commercializes medicines that target specific genomic alterations in cancer cells. Their main products include AYVAKIT/AYVAKYT (avapritinib) for the treatment of systemic mastocytosis and gastrointestinal stromal tumors (GIST), and GAVRETO (pralsetinib) for the treatment of RET-altered cancers.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $128.18m | $177.16m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $138.16m | $181.18m | - | $-18000.0 | 0.00% | 0.01% |
| March 31, 2024 | $96.12m | $7.18m | - | $-167763000.0 | 0.00% | 2337.83% |
Company Impact
Help us evaluate Blueprint Medicines Corp's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.